Form 4: Rapport Therapeutics Director Receives Stock Option Grant

Director Paul M. Silva was granted 15,200 stock options in Rapport Therapeutics, Inc. as part of standard equity compensation.

Summary

• Director Paul M. Silva received a grant of 15,200 stock options on June 10, 2026.
• The options have an exercise price of $35.21 per share.
• The options are set to expire on June 10, 2036.
• Vesting occurs on the earlier of June 10, 2027, or the date of the next Annual Meeting of Stockholders, contingent on continued service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations or financial health.

Positives

• Aligns director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Market volatility could impact the value of the options relative to the exercise price.
• Future share price performance is required for the options to provide economic benefit to the holder.

Future Outlook

The options vest in one year, indicating a standard retention and alignment incentive for the director.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice in the biotechnology sector to ensure board members remain incentivized to oversee long-term strategic growth.

Comparison to Industry Standards

• The vesting schedule of one year is consistent with typical annual equity grants for board members in mid-cap biotech firms.

Corporate Governance

Stakeholder Impact

• Minor dilution impact for existing shareholders upon potential future exercise of options.

Next Steps

• Vesting of options on June 10, 2027 or the next Annual Meeting of Stockholders.

Key Dates

Keywords

Rapport Therapeutics, RAPP, Form 4, Insider Trading, Stock Options, Director Compensation